McMaster University spin-off company Fusion Pharmaceuticals announced it has entered a 15-year lease agreement with the school for a new manufacturing facility for therapeutic pharmaceuticals near its campus in Hamilton, Ontario.
McMaster will build the 27,000-sq-ft facility and Fusion will equip and validate it to support manufacturing of Fusion's pipeline of targeted alpha therapies used in cancer treatment, according to the company.
Fusion stated it expects the manufacturing facility will be up and running by early 2024.